Lupin gets USFDA nod for generic pain drug, osteoarthritis
Drug maker Lupin on Tuesday said it has received approval from the US health regulator to market Meloxicam capsules, used to treat osteoarthritis pain, in the American market.
migrator
Mumbai
It has received approval from the US Food and Drug Administration (USFDA) for meloxicam capsules in strength of 5 mg and 10 mg, Lupin Ltd said in a statement. The company's product is the generic version of Zyla Life Sciences US, Inc's Vivlodex capsules, it added. "The product would be manufactured at company's Aurangabad facility, and is expected to be launched shortly," the drug maker said.
Meloxicam capsules, 5 mg and 10 mg, are indicated for management of osteoarthritis (OA) pain. According to IQVIA MAT March 2020 data, Meloxicam capsules had annual sales of around $14 million in the US.
Visit news.dtnext.in to explore our interactive epaper!
Download the DT Next app for more exciting features!
Click here for iOS
Click here for Android
